Literature DB >> 2313850

Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project.

H D Scott1, A Thacher-Renshaw, S E Rosenbaum, W J Waters, M Green, L G Andrews, G A Faich.   

Abstract

The Food and Drug Administration, Rockville, Md, contracted with the Rhode Island Department of Health, Providence, to conduct a project to increase reporting of suspected adverse drug reactions through physician education. Voluntary reporting, an important part of postmarketing surveillance that signals potential problems with marketed drugs, historically has been underused by physicians. After 2 years, there was a more than 17-fold increase in reports submitted directly from Rhode Island compared with the yearly average before initiation of the project. Increases in the total numbers of reports were paralleled by significant increases in the numbers of reports of severe reactions. Similar increases were not experienced nationally. Physicians in Rhode Island were surveyed before and 2 years after interventions began to determine changes in knowledge and attitudes about reporting of adverse drug reactions. Significant gains in knowledge and positive attitudes toward the reporting system occurred. We conclude that physicians can be stimulated to increase their reporting of suspected reactions, thereby improving the viability of the federal reporting system.

Mesh:

Year:  1990        PMID: 2313850

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  33 in total

1.  Reporting of adverse drug reactions by poison control centres in the US.

Authors:  P A Chyka; S W McCommon
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 2.  Communication of medical product risk: how effective is effective enough?

Authors:  Stephen A Goldman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal.

Authors:  Maria Teresa Herdeiro; Inês Ribeiro-Vaz; Mónica Ferreira; Jorge Polónia; Amílcar Falcão; Adolfo Figueiras
Journal:  Drug Saf       Date:  2012-08-01       Impact factor: 5.606

4.  Texas pharmacists' opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study.

Authors:  Paul Gavaza; Carolyn M Brown; Star Khoza
Journal:  Pharm World Sci       Date:  2010-07-23

5.  [Comprehension and evaluation of drug risks through spontaneous notification].

Authors:  E Weidmann; G Jüngst
Journal:  Infection       Date:  1991       Impact factor: 3.553

6.  A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme.

Authors:  Robert C G Bracchi; Jane Houghton; Fiona J Woods; Simon Thomas; Simon A Smail; Philip A Routledge
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

7.  Physicians' attitudes and adverse drug reaction reporting : a case-control study in Portugal.

Authors:  Maria T Herdeiro; Adolfo Figueiras; Jorge Polónia; Juan Jesus Gestal-Otero
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

8.  The effect of message type on physician compliance with disease reporting requirements.

Authors:  Ian Brissette; Kitty H Gelberg; Anthony J Grey
Journal:  Public Health Rep       Date:  2006 Nov-Dec       Impact factor: 2.792

Review 9.  Determinants of under-reporting of adverse drug reactions: a systematic review.

Authors:  Elena Lopez-Gonzalez; Maria T Herdeiro; Adolfo Figueiras
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain.

Authors:  Consuelo Pedrós; Antoni Vallano; Gloria Cereza; Gemma Mendoza-Aran; Antònia Agustí; Cristina Aguilera; Immaculada Danés; Xavier Vidal; Josep M Arnau
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.